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Introduction: L-carnitine is an important metabolic mediator involved in fatty acid transport. It is obtained from
the diet, particularly from animal products, such as red meat. Previous reports have revealed that long-term tube
feeding with a commercial product containing no or low levels of carnitine can lead to an altered mental state
caused by hyperammonemia.
Case presentation: A 72-year-old Japanese man had a 12-year history of amyotrophic lateral sclerosis. He was
bedridden and had required mechanical ventilation and enteral tube feeding for 10 years at home. His main enteral
solution was a commercial product that contained low carnitine levels, and he sometimes received coffee and
homemade products such as miso soup. Our patient’s ability to communicate gradually deteriorated over a period
of one year. His serum total carnitine level was abnormally low, at 26.7μmol/L (normal range, 45 to 91μmol/L), but
his ammonium level was normal. His mental state improved dramatically after starting L-carnitine supplementation
(600mg twice daily).
Conclusion: This case highlights the importance of avoiding carnitine deficiency in patients with amyotrophic
lateral sclerosis undergoing long-term tube feeding. These patients experience progressive muscle atrophy that
might cause impaired carnitine storage and might manifest as communication difficulties. Carnitine deficiency can
be misdiagnosed as a progression of systemic muscle atrophy. Clinicians should be aware of this disorder and
should consider periodically measuring carnitine levels, regardless of the patient’s serum ammonium levels.
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L-carnitine is a natural constituent of higher organisms,
including animal cells [1]. It is mainly obtained from
dietary sources, particularly red meat and dairy products.
Previous reports have revealed that long-term tube fee-
ding with commercial products containing low or no
carnitine can contribute to altered mental states caused
by hyperammonemia [2]. Lack of carnitine causes the
accumulation of unoxidized fatty acids, which inhibit the
urea cycle, resulting in hyperammonemia. Adults with* Correspondence: issenaohi@yahoo.co.jp
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reproduction in any medium, provided the orchronic illnesses such as advanced cancer and chronic
renal failure with hemodialysis are prone to carnitine
deficiency because of decreased intake, increased uti-
lization, or increased elimination of carnitine. Intra-
venous L-carnitine treatment improved patient-assessed
fatigue in patients undergoing hemodialysis [3]. However,
L-carnitine supplementation to treat carnitine deficiency
did not improve fatigue in patients with invasive malig-
nancies and good performance status [4].
Amyotrophic lateral sclerosis (ALS) is a progressive
neurodegenerative disease that results in severe muscle
atrophy. There is no effective treatment, and patients
with ALS usually require mechanical ventilation and long-
term tube feeding. We describe the case of a patient with. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mental state deteriorated because of carnitine deficiency,
despite normal ammonium levels.Case presentation
A 72-year-old Japanese man had a 12-year history of
ALS. He was bedridden and had been on mechanical
ventilation and percutaneous endoscopic gastrostomy
(PEG) tube feeding at home for the previous 10 years.
He was fed 1000mL (1000kcal) of a commercial product
(Ensure liquid®; Abbott Japan, Tokyo, Japan) containing
<1nmol/mL of carnitine per day. He was also sometimes
given homemade products such as miso soup and coffee
with milk, all via the PEG tube. Over one year, his ability
to communicate using facial expressions gradually dete-
riorated. He was still able to flex his left toe to control
the communication device, but his energy appeared to
diminish when attempting to focus on communication.
He did not have muscle cramps, and his diabetes melli-
tus was well controlled with 25mg of alogliptin without
renal insufficiency. His medical history included a co-
lonic polyp, which was resected via endoscopy four years
previously, and pneumothorax, which was treated con-
servatively one year previously. He had no history of
rhabdomyolysis.
Laboratory evaluations performed to determine the
cause of his altered mental state showed that his electro-
lytes, hematological parameters, including HbA1c, and
liver and renal function parameters were within normal
ranges (Table 1). However, his serum total carnitine was
abnormally low, at 26.7μmol/L (normal range, 45 to
91μmol/L), as were his free carnitine (20.6μmol/L;
normal range, 36 to 74μmol/L) and acylcarnitine ester
(6.1μmol/L; normal range, 6 to 23μmol/L) levels. However,Table 1 Laboratory tests (29 June 2012)
Parameter Laboratory result
White blood cells 5800/μL
Red blood cells 419 × 104/μL
Hemoglobin 12.3g/dL










aNational Glycohemoglobin Standardization Program.his ammonium level was normal (48μg/dL; normal range,
12 to 68μg/dL).
Within two weeks of starting carnitine supplementa-
tion (600mg twice daily via the PEG tube), our patient’s
mental state improved to the level noted the previous
year. His serum total carnitine recovered to 172.3μmol/L
(normal range, 45 to 91μmol/L) one year after starting car-
nitine supplementation. His free carnitine (140.6μmol/L;
normal range, 36 to 74μmol/L) and acylcarnitine ester
(31.7μmol/L; normal range, 6 to 23μmol/L) levels had also
recovered at this time. Our patient’s mental state has been
maintained since starting carnitine supplementation.
Discussion
L-carnitine is found in a variety of food sources but is
highly abundant in animal products. Ensure liquid® is
made from soybeans and casein, which are low in car-
nitine [5]. Our patient was given coffee with milk, but
his total dietary carnitine intake appeared to be low. In
healthy individuals, low carnitine intake does not always
lead to carnitine deficiency because of abundant muscle
stores, efficient reabsorption in the kidneys, and en-
dogenous synthesis in the liver from lysine and methio-
nine, which are present in sufficient amounts in Ensure
liquid®. Normally, more than 95% of the body’s total car-
nitine content would be stored in skeletal muscle [6,7].
However, in patients with ALS, severe muscle atrophy
could reduce the carnitine stores, thus contributing to
secondary carnitine deficiency caused by long-term en-
teral feeding with low-carnitine products.
Decreased plasma carnitine levels are an early marker
of impending secondary carnitine deficiency in tissues.
Low carnitine levels result in the accumulation of unoxi-
dized fatty acids, causing hyperammonemia through in-
hibition of the urea cycle. Indeed, carnitine deficiencyParameter Laboratory result
Total cholesterol 157mg/dL
Triglyceride 165mg/dL
High density lipoprotein cholesterol 33mg/dL
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[8,9]. However, hyperammonemia was not seen in our
patient. Anticonvulsants such as phenytoin and valproate
[5,8] and long-term administration of pivalate-containing
antibiotics [10] have been reported to lower carnitine
levels. Our patient did not take any drugs known to re-
duce carnitine levels.
Measuring plasma carnitine levels may help clinicians
to differentiate between the progression of ALS and car-
nitine deficiency in patients with gradual impairments in
communication, especially in patients receiving long-term
tube feeding with commercial products. In transgenic
mouse models with similar phenotypes to ALS in humans,
muscle apoptosis was prevented by L-carnitine supple-
mentation [11]. However, further research on L-carnitine
supplementation is needed to confirm its role in preven-
ting disease progression in patients with ALS.
Conclusions
Patients with ALS experience progressive muscle atro-
phy; therefore, it is inevitable that they will lose the abi-
lity to communicate over time. Many Japanese patients
with ALS requiring PEG feeding are given nutritional
products approved by the Ministry of Health, Labor and
Welfare that are made from soybeans and casein, but
frequently contain low levels of L-carnitine. To avoid
gradual impairments in communication caused by sec-
ondary carnitine deficiency, clinicians should be aware
of and regularly measure their patients’ carnitine levels,
regardless of their serum ammonia levels. If carnitine
supplementation is necessary, it should be administered
in the form of L-carnitine tablets or other products con-
taining carnitine.
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